Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 157

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 157
---
 March 2024, Dr. Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr. Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana- Farber Cancer Center. Dr. Baek received her MD, MS and PhD at The Catholic University of Korea. Family Relationships There are no family relationships among any of ParentCo’s directors or executive officers. Corporate Governance Composition of the ParentCo Board ParentCo’s business and affairs are organized under the direction of its board of directors. Chris Kim serves as Chair of the Board. The primary responsibilities of the ParentCo Board are to provide oversight, strategic guidance, counseling and direction to ParentCo’s management. The ParentCo Board will meet on a regular basis and additionally as required. In accordance with the terms of the ParentCo Bylaws, the ParentCo Board may establish the authorized number of directors from time to time by resolution. The ParentCo Board consists of four (4) members. In accordance with the ParentCo Certificate of Incorporation, the ParentCo Board are divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. ParentCo’s directors are divided among the three classes as follows:

| ● | the Class I director is Mr. Nicholas Fernandez and Dr. Ji Yeon Baek, with a term that will expire at the annual meeting of stockholders to be held in 2026; |

| ● | the Class II director is Dr. Eun Sook Lee, with a term that will expire at the annual meeting of stockholders to be held in 2027; and |

| ● | the Class III director is Mr. Chris Kim, with a term that will expire at the annual meeting of stockholders to be held in 2028. |

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of the ParentCo Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. Director Independence ParentCo is required to comply with the applicable rules of Nasdaq in determining whether a director is independent. ParentCo undert